Ironwood Pharmaceuticals Stock News

If you are looking for stocks that are well positioned to maintain their recent uptrend, Ironwood (IRWD) could be a great choice. It is one of the several stocks that passed through our "Recent Price

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its fourth quarter and full year 2023 investor update conference call and webcast at 8:30 a.m. Easte

The consensus price target hints at a 37.6% upside potential for Ironwood (IRWD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that Tom McCourt, CEO, will present at the 42nd Annual J.P. Morgan Healthcare C

Ironwood's (IRWD) third-quarter 2023 earnings miss estimates, while revenues beat the same. Linzess collaboration revenues drive the top line.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD ) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ET Company Participants Matt Roache - Director of Investor Relations Tom McCourt - Chief Executi

Ironwood Pharmaceuticals, Inc. is a Boston-based drug company focused on developing treatments for gastrointestinal disorders. The company's revenue-generating product is Linzess, which is approved fo

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a leading global gastrointestinal healthcare company, will present findings during the 2023 North American Society for Pediatric

Ironwood (IRWD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the ro

Ironwood Pharmaceuticals specializes in the development and commercialization of drugs for gastrointestinal diseases, with a focus on conditions like irritable bowel syndrome and chronic constipation.

Ironwood (IRWD) reports loss for second-quarter 2023. The top line increases year over year, driven by growth in Linzess collaboration revenues.

Having ended 2022 on a low note, U.S. market indexes have overall shown stronger performances so far in 2023.

Ironwood (IRWD) lead drug Linzess gets FDA approval for pediatric functional constipation The label expansion of the drug is expected to boost the company's sales.

Ironwood's drug Linzess is seeing its sales start to plateau. It could get an expanded indication for Linzess that delays a decline in revenue.

Ironwood (IRWD) offers to acquire VectivBio, which will help strengthen its gastrointestinal treatment portfolio.